Previous 10 | Next 10 |
SALT LAKE CITY, Feb. 28, 2019 (GLOBE NEWSWIRE) -- Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in the use of data analytics for disease identification and subsequent therapeutic intervention through precision therapeutic treatments, announces that Jay M. Moyes has been named...
Puma Biotechnology (NYSE: PBYI ) is scheduled to announce Q4 earnings results on Thursday, February 28th, after market close. The consensus EPS Estimate is -$0.69 (+33.0% Y/Y) and the consensus Revenue Estimate is $53.65M (+148.4% Y/Y). Over the last 2 years, PBYI has beaten EPS estim...
ACHC , ADSK , AGO , AIMT , ALRM , ALTR , AMBC , AMC , APPF , AQN , ATRC , BIO , BLDR , CARG , CISN , CSLT , DCO , DDD , DELL , EDIT , EIX , EQH , FTCH , GCAP , GPS , GSBD , HABT , ICUI , JAG , JWN , KTOS , KWR , LYV , MAIN , MAR , MAXR , MTZ , NKTR , N...
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PST/4:30 p.m. EST on Thursday, February 28, 2019 following release of its fourth quarter and full year 2018 financial results. The call may be accessed by dialing 1-877-709...
On February 6, 2019, MacroGenics ( MGNX ) reported that the SOPHIA trial comparing margetuximab plus chemotherapy to Herceptin plus chemotherapy met the primary endpoint of progression free survival with a hazard ratio of 0.76 with an accompanying p-value of 0.033. This rather surprising res...
"Marge" Bests Herceptin The treatment of HER2+ breast cancer was revolutionized by approval of Roche's (RHHBY) Herceptin (trastuzumab) in the late 90s. In the past two decades, Herceptin has saved thousands of lives and registered over $75 billion in global sales. Since that time, HER2 h...
Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced today that the class action lawsuit, Hsu vs. Puma Biotechnology, Inc., et. al. , filed in the U.S. District Court for the Central District of California against Puma and Alan H. Auerbach, Puma’s CEO and P...
Jefferies healthcare strategist Jared Holtz is a short-term biotech bear saying that profit-taking "makes sense" through this earnings season considering the sector's market-leading performance so far this year. He thinks the SPDR S&P Biotech ETF ( XBI -1.3% ) could drop to $75 ( -6% )...
Thesis We sold our position in Tesaro ( TSRO ) and are increasing our exposure to Puma Biotechnology ( PBYI ) as we think that Puma can be a good acquisition target as a small-cap, $250 million sales, oncology company with promising growth prospects. Puma is expected to become cash flow ...
Please note that I am affiliated with Avisol Capital Partners and their Total Pharma Tracker service. They have also covered the companies in this article in their writings, and I wanted to make readers aware of the potential for overlapping coverage. If you're interested in this serv...
News, Short Squeeze, Breakout and More Instantly...
Puma Biotechnology Inc Company Name:
PBYI Stock Symbol:
NASDAQ Market:
Puma Biotechnology Inc Website:
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PDT/4:30 p.m. EDT on Thursday, August 1, 2024, following the release of its second quarter 2024 financial results. The call may be accessed by dialing 1-877-709-8150 (domestic) or 1-...
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the presentation of alisertib for the treatment of patients with advanced osimertinib-resistant epidermal growth factor receptor-mutated (EGFR-mutated) non-small cell lung cancer (NCT04085315) at the 2024 American Soc...
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the presentation of biomarker findings from a Phase II randomized clinical trial of alisertib alone vs. alisertib + fulvestrant for the treatment of patients with endocrine and CDK4/6 inhibitor (CDK 4/6i) resistant, h...